Table 2

Cost-effectiveness of childhood cancer treatments

Study	Year	Country	Diagnosis	Inputs included in cost analysis*	Cost per treated patient (2018 USD)	Proportion of patients with 5-year survival	Cost per life saved (2018 USD)	DALYs averted per treated patient using 3% discounting	Cost per DALY averted (2018 USD)	GDP per capita (2017: latest available, USD)
Multiple childhood cancers
Fuentes-Alabi et al18	2018	El Salvador	All childhood cancers	Comprehensive	30 035	0.49	61 296	36	1699	3889.31
Renner et al16	2018	Ghana	All childhood cancers	Comprehensive	10 540	0.35	30 115	27	1114	2046.11
Leukaemias
Jaime-Perez et al40	2017	Mexico	ALL	Medium	24 788	0.55	45 069	30	1490	8910.33
Gao et al31	2013	China	ALL	Low	27 209	0.50 (5-year EFS)	45 348	30	1505	8826.99
Gu et al34	2008	China	ALL	Low	44 667	0.67 (5-year EFS)	66 667	30	2213	8826.99
Hayati et al35	2018	Iran	ALL	Medium	16 914	Not reported	Unable to calculate	QALYs gained per patient (5-year analysis period): 3.78	4475	5593.85
Luo et al46	2008	China	ALL	Medium	18 791	0.78 (7-year EFS)	24 091	30	800	8826.99
Luo et al47	2009	China	APL	Low	24 704	0.38 (3.5-year EFS)	65 011	30	2158	8826.99
Burkitt lymphoma
Denburg et al30	2019	Uganda	BL	Comprehensive	1401	0.55 (2-year survival)	2574	26	100	606.47
Hesseling et al37	2003	Malawi	BL	Low	217	0.35 (1-year EFS 0.57 converted to 5-year OS)	620	28	22	338.48
Other
Stefan and Stones 52	2009	South Africa	HL	Low	7360	0.76	9684	28	346	6151.08
Waddell et al54	2015	Uganda	Retinoblastoma	Low	1079	0.37	2916	20	146	606.47

*Comprehensive: ≥10 inputs, Medium: 5–9 inputs, Low: <5 inputs.
ALL, acute lymphoblastic leukaemia; APL, acute promyelocytic leukaemia; BL, Burkitt lymphoma; DALY, disability-adjusted life year; EFS, event-free survival; GDP, gross domestic product; HL, Hodgkin lymphoma; OS, overall survival; QALY, quality-adjusted life year.